查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2022731

全球製藥自動化市場（按產品、自動化方式、最終用戶和地區分類）：預測（至 2036 年）

Pharmaceutical Automation Market Size, Share, Forecast, & Trends Analysis by Offering, Mode of Automation, End User, & Geography - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 330 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

全球製藥自動化市場預計將從2026年的約149.9億美元成長至2036年的約395.7億美元，預測期內（2026-2036年）複合年成長率（CAGR）為10.2%。製藥自動化市場的強勁成長主要得益於「製藥4.0」的加速轉型，該轉型透過整合先進的機器人技術、人工智慧和工業IoT（IIoT），重新定義了製藥生產的效率、擴充性和合規性。

由於人口老化和慢性病盛行率上升，全球對救命藥物、生物製藥和個人化醫療的需求持續激增，製藥和生物技術公司正日益轉向自動化系統，以滿足監管機構對高產量和嚴格品質保證的要求。從先進的工廠級控制系統（如DCS和SCADA）到精密的機械臂和機器視覺系統，自動化解決方案能夠幫助製造商最大限度地減少人為錯誤，降低污染風險，並確保整個生產生命週期中資料的絕對完整性。此外，連續生產和即時放行檢測的擴展對更先進的流程自動化和數位化同步提出了更高的要求。將數位雙胞胎技術與實際生產環境結合，能夠幫助企業大幅最佳化開發成本和轉換時間。同時，以永續發展為導向的自動化有助於減少溶劑消耗和能源浪費。隨著新興市場對製造基礎設施的大量投資，以及協作機器人（cobot）在實驗室和生產設施中應用日益廣泛，在科技巨頭和專業自動化供應商的主導，製藥自動化生態系統正蓄勢待發，即將迎來一個充滿變革的十年。

目錄

第1章：引言

第2章 分析方法

第3章摘要整理

  • 市場分析：透過提供內容
  • 市場分析：透過自動化方法
  • 市場分析：依最終用戶分類
  • 市場分析：按地區分類
  • 競爭分析

第4章 市場洞察

  • 市場促進因素
    • 擴大人工智慧和先進分析技術在製藥生產的應用
    • 擴大連續生產和即時放行測試
    • 對生物製藥、細胞和基因療法以及高精度製造的需求不斷成長。
    • 監管機構強調資料完整性和數位合規性
  • 市場限制因素
    • 大筆資本投入和較長的實施週期
    • 與傳統製造系統整合面臨的挑戰
  • 市場機遇
    • 工業物聯網、基於雲端的自動化和邊緣運算的採用
    • 以永續性主導的自動化和能源最佳化
    • 新興市場藥品生產的擴張
  • 市場挑戰
    • 互聯製造生態系中的網路安全風險
    • 高度自動化系統中熟練勞動力短缺
    • 與互通性和標準化相關的挑戰
  • 市場趨勢
    • 數位雙胞胎與模擬技術的融合
    • 擴大機器人和協作機器人（cobot）的應用
    • MES、SCADA、DCS 和先進分析平台的整合。
    • 智慧型檢測系統和基於視覺的品管
  • 波特五力分析
  • 價值鏈分析
    • 組件硬體供應商
    • 自動化硬體和軟體供應商
    • 系統整合商
    • 企業自動化和分析提供者
    • 售後服務、生命週期支持

第5章：製藥自動化市場評估：依產品/服務分類

  • 解決方案
    • 企業級控制
      • 企業資源管理（ERP）
      • 產品生命週期管理（PLM）
      • 製造執行系統（MES）
    • 工廠儀器
      • 感應器
      • 機器人
        • 關節機器人
        • 笛卡兒機器人
        • SCARA（水平關節機器人）
        • 協作機器人
        • 其他機器人
      • 馬達驅動
      • 機器視覺系統
        • 相機
        • 光學/LED照明
      • 繼電器開關
      • 其他工廠儀器解決方案
    • 工廠級管制
      • 可程式邏輯控制器（PLC）
      • 分散式控制系統（DCS）
      • 監控與數據採集（SCADA）
      • 其他工廠級控制
  • 服務
    • 整合和實施服務
    • 維護和支援服務
    • 諮詢、培訓和顧問服務
    • 安全保全服務

第6章：製藥自動化市場評估：依自動化方法分類

  • 半自動系統
  • 全自動系統

第7章：製藥自動化市場評估：依最終用戶分類

  • 主要製藥商
    • 小分子藥物生產商（口服和注射劑型）
    • 生技藥品和生物相似藥生產商
    • 疫苗生產商
    • 其他
  • 合約研發生產組織（CDMO）
  • 生物技術和先進治療公司
    • 細胞和基因治療開發公司
    • mRNA和新平台開發公司
    • 其他

第8章：製藥自動化市場分析：按地區分類

  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 荷蘭
    • 瑞典
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 其他亞太國家
  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 南非
    • UAE
    • 沙烏地阿拉伯
    • 其他中東和非洲國家

第9章 競爭分析

  • 關鍵成長策略
  • 競爭性標竿分析
  • 競爭對手儀表板
    • 產業領導者
    • 市場差異化因素
    • 先鋒公司
    • 新興企業
  • 市佔率分析

第10章：公司簡介

  • Siemens AG（Germany）
  • Emerson Electric Co.（US）
  • Mitsubishi Electric Corporation（Japan）
  • ABB Ltd（Switzerland）
  • FANUC CORPORATION（Japan）
  • Honeywell International Inc.（US）
  • KUKA AG（Germany）
  • Schneider Electric SE（France）
  • Rockwell Automation, Inc.（US）
  • YASKAWA Electric Corporation（Japan）
  • Yokogawa Electric Corporation（Japan）
  • OMRON Corporation（Japan）
  • Advantech Co., Ltd.（Taiwan）
  • Fuji Electric Co., Ltd.（Japan）
  • Syntegon Technology GmbH（Germany）
  • Others

第11章附錄

簡介目錄
Product Code: MRSE - 104594

Pharmaceutical Automation Market by Offering (Solutions, Services), Mode of Automation (Semi-automatic, Fully Automatic), and End User (Large Pharmaceutical Manufacturers, CDMOs, Biotech) - Global Forecast to 2036

According to the latest research report titled, 'Pharmaceutical Automation Market by Offering (Solutions, Services), Mode of Automation (Semi-automatic, Fully Automatic), and End User (Large Pharmaceutical Manufacturers, CDMOs, Biotech) - Global Forecast to 2036,' the global pharmaceutical automation market is projected to reach approximately USD 39.57 billion by 2036 from an estimated USD 14.99 billion in 2026, at a CAGR of 10.2% during the forecast period (2026-2036). The robust growth of the pharmaceutical automation market is fundamentally driven by the accelerating transition towards Pharma 4.0, where the integration of advanced robotics, artificial intelligence, and the Industrial Internet of Things (IIoT) is redefining the efficiency, scalability, and compliance of pharmaceutical manufacturing.

As global demand for life-saving drugs, biologics, and personalized medicines continues to surge-exacerbated by aging populations and the rising prevalence of chronic diseases-pharmaceutical and biotech companies are increasingly turning to automated systems to achieve the high production throughput and stringent quality assurance required by regulatory bodies. Automated solutions, ranging from sophisticated plant-level controls like DCS and SCADA to advanced robotic arms and machine vision systems, are enabling manufacturers to minimize human error, reduce contamination risks, and ensure absolute data integrity throughout the production lifecycle. Furthermore, the expansion of continuous manufacturing and real-time release testing is necessitating a higher degree of process automation and digital synchronization. The convergence of digital twin technologies with real-world manufacturing environments is allowing companies to optimize development costs and switch times significantly, while sustainability-driven automation is helping reduce solvent consumption and energy waste. With significant investments in manufacturing infrastructure across emerging markets and the increasing adoption of collaborative robots (cobots) in lab and production settings, the pharmaceutical automation ecosystem is poised for a decade of transformative innovation, led by global technology giants and specialized automation providers.

Market Segmentation

The pharmaceutical automation market is segmented by offering (solutions and services), mode of automation (semi-automatic systems and fully automatic systems), end user (large pharmaceutical manufacturers, contract development & manufacturing organizations [CDMOs], and biotechnology & advanced therapy companies), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Offering

By offering, the solutions segment holds the largest share of the overall pharmaceutical automation market in 2026. This dominance is attributed to the substantial demand for plant instrumentation, including robots, sensors, and machine vision systems, alongside plant-level controls such as Programmable Logic Controllers (PLC) and Distributed Control Systems (DCS) that form the backbone of automated manufacturing. However, the services segment is expected to witness significant growth during the forecast period, driven by the increasing complexity of integrating Pharma 4.0 technologies with legacy systems, necessitating professional advisory, installation, and ongoing maintenance and security services.

Based on Mode of Automation

By mode of automation, the fully automatic systems segment is expected to witness the fastest growth and hold a significant share of the market during the forecast period. The shift toward full automation is driven by the need for high-speed, high-volume production with minimal human intervention, particularly in sterile environments and for high-potency drug manufacturing. Fully automated lines provide superior consistency and traceability, which are critical for meeting the stringent quality standards of the pharmaceutical industry.

Based on End User

By end user, the large pharmaceutical manufacturers segment holds the largest share of the overall pharmaceutical automation market in 2026, as these organizations possess the capital and scale to implement comprehensive enterprise-level and plant-wide automation solutions. However, the Contract Development & Manufacturing Organizations (CDMOs) segment is projected to register the fastest growth during the forecast period. The rise of CDMOs is fueled by the pharmaceutical industry's increasing reliance on outsourcing to gain specialized manufacturing expertise and flexibility, leading CDMOs to invest heavily in advanced automation to offer competitive, high-quality, and scalable production services to their clients.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). In 2026, Europe holds the largest share of the overall pharmaceutical automation market, supported by the presence of numerous leading pharmaceutical companies and a strong heritage of industrial engineering and automation innovation. However, Asia-Pacific is expected to witness the fastest growth during the forecast period. This growth is driven by the massive expansion of pharmaceutical manufacturing in China and India, increasing government support for industrial automation, and the rising adoption of high-tech manufacturing solutions to meet both domestic healthcare needs and global export standards.

Key Players

The key players operating in the overall pharmaceutical automation market include Siemens AG (Germany), Emerson Electric Co. (U.S.), Mitsubishi Electric Corporation (Japan), ABB Ltd (Switzerland), FANUC CORPORATION (Japan), Honeywell International Inc. (U.S.), KUKA AG (Germany), Schneider Electric SE (France), Rockwell Automation, Inc. (U.S.), YASKAWA Electric Corporation (Japan), Yokogawa Electric Corporation (Japan), OMRON Corporation (Japan), Advantech Co., Ltd. (Taiwan), Fuji Electric Co., Ltd. (Japan), and Syntegon Technology GmbH (Germany).

Key Questions Answered in the Report-

  • What is the current revenue generated by the pharmaceutical automation market?
  • At what rate is the pharmaceutical automation market demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the pharmaceutical automation market?
  • What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of offering, mode of automation, and end user are expected to create major traction for the vendors in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the pharmaceutical automation market?
  • Who are the major players in the pharmaceutical automation market? What are their specific product and service offerings in this market?
  • What are the recent strategic developments in the pharmaceutical automation market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Pharmaceutical Automation Market Assessment -- by Offering

  • Solutions
    • Enterprise-level Controls (PLM, ERP, MES)
    • Plant Instrumentation (Robots, Sensors, Machine Vision Systems, Motors & Drives, Relays & Switches)
    • Plant-level Controls (SCADA, DCS, PLC)
  • Services
    • Integration & Installation Services
    • Maintenance & Support Services
    • Advisory, Training, and Consulting Services
    • Safety & Security Services

Pharmaceutical Automation Market Assessment -- by Mode of Automation

  • Semi-automatic Systems
  • Fully Automatic Systems

Pharmaceutical Automation Market Assessment -- by End User

  • Large Pharmaceutical Manufacturers
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Biotechnology & Advanced Therapy Companies

Pharmaceutical Automation Market Assessment -- by Geography

  • Europe
    • Germany
    • U.K.
    • Italy
    • Netherlands
    • Sweden
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Singapore
    • Rest of Asia-Pacific
  • North America
    • U.S.
    • Canada
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research & Validation
      • 2.2.2.1. Primary Interviews with Experts
      • 2.2.2.2. Approaches for Country-/Region-Level Analysis
  • 2.3. Market Estimation
    • 2.3.1. Bottom-Up Approach
    • 2.3.2. Top-Down Approach
    • 2.3.3. Growth Forecast
  • 2.4. Data Triangulation
  • 2.5. Assumptions for the Study

3. Executive Summary

  • 3.1. Overview
  • 3.2. Market Analysis, by Offering
  • 3.3. Market Analysis, by Mode of Automation
  • 3.4. Market Analysis, by End User
  • 3.5. Market Analysis, by Geography
  • 3.6. Competitive Analysis

4. Market Insights

  • 4.1. Overview
  • 4.2. Market Drivers
    • 4.2.1. Rising Adoption of AI and Advanced Analytics in Pharmaceutical Manufacturing
    • 4.2.2. Expansion of Continuous Manufacturing and Real-Time Release Testing
    • 4.2.3. Increasing Demand for Biologics, Cell & Gene Therapy, and High-Precision Manufacturing
    • 4.2.4. Regulatory Emphasis on Data Integrity and Digital Compliance
  • 4.3. Market Restraints
    • 4.3.1. High Capital Investment and Long Implementation Cycles
    • 4.3.2. Integration Challenges with Legacy Manufacturing Systems
  • 4.4. Market Opportunities
    • 4.4.1. Adoption of IIoT, Cloud-Based Automation, and Edge Computing
    • 4.4.2. Sustainability-Driven Automation and Energy Optimization
    • 4.4.3. Expansion of Pharmaceutical Manufacturing in Emerging Markets
  • 4.5. Market Challenges
    • 4.5.1. Cybersecurity Risks in Connected Manufacturing Ecosystems
    • 4.5.2. Shortage of Skilled Workforce for Advanced Automation Systems
    • 4.5.3. Interoperability and Standardization Issues
  • 4.6. Market Trends
    • 4.6.1. Integration of Digital Twin and Simulation Technologies
    • 4.6.2. Growing Deployment of Robotics and Collaborative Robots (Cobots)
    • 4.6.3. Convergence of MES, SCADA, DCS, and Advanced Analytics Platforms
    • 4.6.4. Smart Inspection Systems and Vision-Based Quality Control
  • 4.7. Porter's Five Forces Analysis
    • 4.7.1. Threat of New Entrants
    • 4.7.2. Bargaining Power of Suppliers
    • 4.7.3. Bargaining Power of Buyers
    • 4.7.4. Threat of Substitutes
    • 4.7.5. Competitive Rivalry
  • 4.8. Value Chain Analysis
    • 4.8.1. Component and Hardware Suppliers
    • 4.8.2. Automation Hardware & Software Providers
    • 4.8.3. System Integrators
    • 4.8.4. Enterprise Automation & Analytics Providers
    • 4.8.5. Aftermarket Services and Lifecycle Support

5. Pharmaceutical Automation Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Solutions
    • 5.2.1. Enterprise-Level Controls
      • 5.2.1.1. Enterprise Resource Planning (ERP)
      • 5.2.1.2. Product Lifecycle Management (PLM)
      • 5.2.1.3. Manufacturing Execution Systems (MES)
    • 5.2.2. Plant Instrumentation
      • 5.2.2.1. Sensors
      • 5.2.2.2. Robots
        • 5.2.2.2.1. Articulated Robots
        • 5.2.2.2.2. Cartesian Robots
        • 5.2.2.2.3. Selective Compliance Assembly Robot Arms (SCARA)
        • 5.2.2.2.4. Collaborative Robots
        • 5.2.2.2.5. Other Robots
      • 5.2.2.3. Motors & Drives
      • 5.2.2.4. Machine Vision Systems
        • 5.2.2.4.1. Cameras
        • 5.2.2.4.2. Optics and LED Lighting
      • 5.2.2.5. Relays & Switches
      • 5.2.2.6. Other Plant Instrumentation Solutions
    • 5.2.3. Plant-Level Controls
      • 5.2.3.1. Programmable Logic Controllers (PLC)
      • 5.2.3.2. Distributed Control Systems (DCS)
      • 5.2.3.3. Supervisory Control and Data Acquisition (SCADA)
      • 5.2.3.4. Other Plant-Level Controls
  • 5.3. Services
    • 5.3.1. Integration & Installation Services
    • 5.3.2. Maintenance & Support Services
    • 5.3.3. Advisory, Training, and Consulting Services
    • 5.3.4. Safety & Security Services

6. Pharmaceutical Automation Market Assessment-by Mode of Automation

  • 6.1. Overview
  • 6.2. Semi-Automatic Systems
  • 6.3. Fully Automatic Systems

7. Pharmaceutical Automation Market Assessment-by End User

  • 7.1. Overview
  • 7.2. Large Pharmaceutical Manufacturers
    • 7.2.1. Small Molecule Manufacturers (OSD & Injectables)
    • 7.2.2. Biologics & Biosimilars Manufacturers
    • 7.2.3. Vaccine Manufacturers
    • 7.2.4. Others
  • 7.3. Contract Development & Manufacturing Organizations (CDMOs)
  • 7.4. Biotechnology & Advanced Therapy Companies
    • 7.4.1. Cell & Gene Therapy Developers
    • 7.4.2. mRNA & Novel Platform Developers
    • 7.4.3. Others

8. Pharmaceutical Automation Market Assessment-by Geography

  • 8.1. Overview
  • 8.2. Europe
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. Italy
    • 8.2.4. Netherlands
    • 8.2.5. Sweden
    • 8.2.6. France
    • 8.2.7. Spain
    • 8.2.8. Rest of Europe
  • 8.3. Asia-Pacific
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. South Korea
    • 8.3.5. Singapore
    • 8.3.6. Rest of Asia-Pacific
  • 8.4. North America
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. Latin America
    • 8.5.1. Mexico
    • 8.5.2. Brazil
    • 8.5.3. Rest of Latin America
  • 8.6. Middle East & Africa
    • 8.6.1. South Africa
    • 8.6.2. UAE
    • 8.6.3. Saudi Arabia
    • 8.6.4. Rest of the Middle East & Africa

9. Competition Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis

10. Company Profiles

  • 10.1. Siemens AG (Germany)
  • 10.2. Emerson Electric Co. (U.S.)
  • 10.3. Mitsubishi Electric Corporation (Japan)
  • 10.4. ABB Ltd (Switzerland)
  • 10.5. FANUC CORPORATION (Japan)
  • 10.6. Honeywell International Inc. (U.S.)
  • 10.7. KUKA AG (Germany)
  • 10.8. Schneider Electric SE (France)
  • 10.9. Rockwell Automation, Inc. (U.S.)
  • 10.10. YASKAWA Electric Corporation (Japan)
  • 10.11. Yokogawa Electric Corporation (Japan)
  • 10.12. OMRON Corporation (Japan)
  • 10.13. Advantech Co., Ltd. (Taiwan)
  • 10.14. Fuji Electric Co., Ltd. (Japan)
  • 10.15. Syntegon Technology GmbH (Germany)
  • 10.16. Others

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports